Search results
Showing 1 to 4 of 4 results for sparsentan
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Awaiting development Reference number: GID-TA10867 Expected publication date: TBC
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.